NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the three months and year ended December 31, 2007. For the three months ended December 31, 2007, the company incurred a net loss attributable to common stockholders of $7.7 million, or $0.16 per share, basic and diluted, compared with a net loss attributable to common stockholders of $11.7 million, or $0.26 per share, basic and diluted, for the same period in 2006. For the year ended December 31, 2007, Antigenics incurred a net loss attributable to common stockholders of $37.6 million, or $0.81 per share, basic and diluted, compared with a net loss attributable to common stockholders of $52.7 million, or $1.15 per share, basic and diluted, for the same period in 2006.
